On the recordJune 4, 2024
This amendment would urge the Veterans Administration to make a decision on incorporating MDMA-assisted therapy into their formulary within 180 days of FDA approval. This is based on legislation by the gentleman from Wisconsin (Mr. Van Orden), which the Committee on Veterans' Affairs approved last month. As we speak, the FDA's Scientific Advisory Committee is meeting to evaluate the phase 3 studies into this therapy, and full approval will likely come in early August. I have had the opportunity to personally meet with many of the researchers involved in this study and the veterans whose lives have been forever changed by these therapies. That experience made the potential of this treatment clear to me, and many of the veterans told me that they would not be alive today if it were not for this therapy. Any bureaucratic red tape that delays potential formulary inclusion could cost the lives of veterans currently suffering from PTSD. This amendment does not push VA to make a decision one way or another. It merely calls for them to act quickly in making a formulary decision. Mr. Chair, I strongly urge my colleagues to support this amendment. Mr. Chair, I yield such time as he may consume to the gentleman from California (Mr. Correa).
